MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis

Damian Tworek, Piotr Kuna, Wojciech Młynarski, Paweł Górski, Tadeusz Pietras, Adam Antczak, Damian Tworek, Piotr Kuna, Wojciech Młynarski, Paweł Górski, Tadeusz Pietras, Adam Antczak

Abstract

Introduction: The role of monokine induced by interferon-γ (IFN-γ, MIG/CXCL9), IFN-γ-inducible protein (IP-10/CXCL10), and IFN-inducible T cell α chemoattractant (I-TAC/CXCL11) in allergic inflammation has not been explored in detail in vivo. The aim of the study was to examine the changes in concentrations of MIG/CXCL9, IP-10/CXCL10 and I-TAC/CXCL11 in nasal lavages collected from healthy and allergic subjects during nasal allergen challenge.

Material and methods: Subjects allergic to grass pollen and healthy controls were included. Nasal allergen challenge preceded by placebo administration was performed outside the pollen season. Nasal lavages were collected before and 30 min after application of the placebo and 30 min after allergen administration. Concentrations of chemokines were determined using ELISA.

Results: We observed significantly higher concentrations of IP-10/CXCL10 in allergic patients compared to the healthy subjects before (354.49 ±329.24 vs. 164.62 ±175.94 pg/ml; p = 0.036), 30 min after placebo (420.3 ±421.28 vs. 246.88 ±353.24 pg/ml; p = 0.021) and 30 min after allergen administration (403.28 ±359.29 vs. 162.68 ±148.69 pg/ml; p = 0.025). IP-10/CXCL10 levels did not change 30 min after allergen provocation. In contrast, MIG/CXCL9 levels were similar in both groups before and after placebo. However, a significant rise in MIG/CXCL9 concentration was noted in allergic patients 30 min after the allergen (138.88 ±109.59 vs. 395.8 ±301.2 pg/ml; p = 0.00026). I-TAC/CXCL11 concentrations increased after placebo as well as the allergen in both groups.

Conclusions: IP-10/CXCL10 concentrations are elevated in nasal lavages from allergic patients and this chemokine may play a role in chronic allergic inflammation. MIG/CXCL9 levels increase rapidly after allergen application, which may suggest its role in the early allergic response. Results on I-TAC/CXCL11 concentrations remain inconclusive.

Keywords: I-TAC; IP-10; MIG; allergic inflammation; rhinitis.

Figures

Figure 1
Figure 1
Changes in IP-10/CXCL10 concentrations during allergen challenge. 1 – before administration of negative control solution; 2 – after administration of negative control solution/before administration of the allergen; 3 – after administration of the allergen
Figure 2
Figure 2
Changes in MIG/CXCL9 concentrations during allergen challenge. 1 – before administration of negative control solution; 2 – after administration of negative control solution/before administration of the allergen; 3 – after administration of the allergen
Figure 3
Figure 3
Changes in I-TAC/CXCL11 concentrations during allergen challenge. 1 – before administration of negative control solution; 2 – after administration of negative control solution/before administration of the allergen; 3 – after administration of the allergen

References

    1. Meller S, Lauerma AI, Kopp FM, et al. Chemokine responses distinguish chemical-induced allergic from irritant skin inflammation: memory T cells make the difference. J Allergy Clin Immunol. 2007;119:1470–80.
    1. Flier J, Boorsma DM, Bruynzeel DP, et al. The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol. 1999;113:574–8.
    1. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194:398–405.
    1. Dajotoy T, Andersson P, Bjartell A, Löfdahl CG, Tapper H, Egesten A. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. J Leukoc Biol. 2004;76:685–91.
    1. Greiff L, Meyer P, Svensson C, Persson CG, Andersson M. The “nasal pool”-device for challenge and lavage of the nasal mucosa in children: histamine-induced plasma exudation responses. Pediatr Allergy Immunol. 1997;8:137–42.
    1. Miotto D, Christodoulopoulos P, Olivenstein R, et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol. 2001;107:664–70.
    1. Hartl D, Griese M, Nicolai T, et al. Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. J Allergy Clin Immunol. 2005;115:728–36.
    1. Lai ST, Hung CH, Hua YM, Hsu SH, Jong YJ, Suen JL. T-helper 1-related chemokines in the exacerbation of childhood asthma. Pediatr Int. 2008;50:99–102.
    1. Medoff BD, Sauty A, Tager AM, et al. IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol. 2002;168:5278–86.
    1. Antczak A, Kuźmińska B, Górski P. 8-isoprostane levels are elevated in nasal lavages from asthmatic patients with allergic rhinitis. Allergy. 2003;58(suppl. 74):74.
    1. Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J Allergy Clin Immunol. 2003;112:930–4.
    1. Fulkerson PC, Zimmermann N, Brandt EB, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9) Proc Natl Acad Sci U S A. 2004;101:1987–92.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다